Publicaciones en las que colabora con Matias Antonio Ávila Zaragozá (24)

2024

  1. SUMOylation controls Hu antigen R posttranscriptional activity in liver cancer

    Cell Reports, Vol. 43, Núm. 3

2023

  1. Identification and experimental validation of druggable epigenetic targets in hepatoblastoma

    Journal of Hepatology, Vol. 79, Núm. 4, pp. 989-1005

  2. The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent

    Hepatology (Baltimore, Md.), Vol. 78, Núm. 3, pp. 878-895

2022

  1. Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions

    Gut, Vol. 71, Núm. 8, pp. 1669-1683

  2. Impact of Liver Inflammation on Bile Acid Side Chain Shortening and Amidation

    Cells, Vol. 11, Núm. 24

  3. Impact of alternative splicing variants on liver cancer biology

    Cancers, Vol. 14, Núm. 1

  4. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming

    Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1

  5. Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models

    Journal of Hepatology, Vol. 77, Núm. 1, pp. 177-190

2021

  1. Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma

    Hepatology, Vol. 73, Núm. 6, pp. 2380-2396

  2. Gene supplementation of CYP27A1 in the liver restores bile acid metabolism in a mouse model of cerebrotendinous xanthomatosis

    Molecular Therapy - Methods and Clinical Development, Vol. 22, pp. 210-221

  3. Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis

    Molecular Metabolism, Vol. 53

2020

  1. A novel serum metabolomic profile for the differential diagnosis of distal cholangiocarcinoma and pancreatic ductal adenocarcinoma

    Cancers, Vol. 12, Núm. 6

  2. Dual pharmacological targeting of hdacs and pde5 inhibits liver disease progression in a mouse model of biliary inflammation and fibrosis

    Cancers, Vol. 12, Núm. 12, pp. 1-27

  3. Multi‐omics integration highlights the role of ubiquitination in ccl4‐induced liver fibrosis

    International Journal of Molecular Sciences, Vol. 21, Núm. 23, pp. 1-19

  4. Pilot multi-omic analysis of human bile from benign and malignant biliary strictures: A machine-learning approach

    Cancers, Vol. 12, Núm. 6, pp. 1-30

2019

  1. Causes of hOCT1-Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor-Selective Gene Therapy

    Hepatology, Vol. 70, Núm. 4, pp. 1246-1261

  2. Epigenetic events involved in organic cation transporter 1-dependent impaired response of hepatocellular carcinoma to sorafenib

    British Journal of Pharmacology, Vol. 176, Núm. 6, pp. 787-800

  3. Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis

    Hepatology, Vol. 70, Núm. 2, pp. 547-562

  4. The Epidermal Growth Factor Receptor Ligand Amphiregulin Protects From Cholestatic Liver Injury and Regulates Bile Acids Synthesis

    Hepatology, Vol. 69, Núm. 4, pp. 1632-1647

2018

  1. Interaction of glucocorticoids with FXR/FGF19/FGF21-mediated ileum-liver crosstalk

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1864, Núm. 9, pp. 2927-2937